LEO Pharma - Articles and news items

AstraZeneca licenses skin disease drugs to LEO Pharma

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.

Enstilar launches in the UK for patients with plaque psoriasis

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Enstilar is the first fixed-combination, cutaneous foam spray for the once-daily topical treatment of all extents of plaque psoriasis…

Enstilar receives scientific approval in the EU for psoriasis

Industry news / 21 March 2016 / Victoria White

Enstilar is a topical spray foam treatment for psoriasis that is designed to provide patients with a convenient treatment option that can be easily applied…

New data for Enstilar foam spray presented at AAD

Industry news / 7 March 2016 / Victoria White

These data show the enhanced local bioavailability of calcipotriol/betamethasone dipropionate in the foam spray vehicle results from supersaturation…

LEO Pharma to acquire global dermatology portfolio from Astellas

Industry news / 11 November 2015 / Victoria White

The transaction will be the largest in LEO Pharma’s more than 100-year history in terms of incremental turnover…


New data shows Enstilar provides rapid itch relief for psoriasis patients

Industry news / 10 June 2015 / Victoria White

New data shows that aerosol foam Enstilar provided rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...